We’re proud to announce that Cleo Skin is now integrated into Proscia’s Concentriq platform, advancing precision and efficiency in digital dermatopathology through AI biomarker detection.

We continue to push the boundaries of AI in pathology, bringing our advanced technology to Proscia, a global leader in digital pathology. Integrated into the Concentriq software platform, Cleo Skin introduces AI-powered biomarker detection for skin tissue, enabling pathologists to work with greater precision, speed, and confidence.

Advancing digital dermatopathology with AI

Dermatopathology is among the most diverse areas of pathology, with more than 500 distinct classifications. This variation is compounded by relatively high pathologist disagreement in some instances. Although overall inter-observer concordance is high (90–95%), certain distinctions, such as differentiating malignant melanoma from benign melanocytic nevi, can remain challenging.

“This addition underscores our commitment to making AI practical where it can have the greatest impact,” said David West, CEO of Proscia. “By expanding our AI offerings in skin, we will enable pathologists to deliver faster, more consistent results in one of the most challenging areas of pathology, all within the workflows they trust.”

Cleo Skin strengthens Concentriq’s position as the most comprehensive digital pathology platform by automatically detecting mitotic figures, mitotic hotspots, and perineural invasion, which are key biomarkers in skin diseases. In combination with lesion classification, including melanoma, basal cell carcinoma, and squamous cell carcinoma, these capabilities help pathologists streamline their workflow.

The application also measures tumor margins and lesion dimensions, providing a comprehensive and reproducible evaluation that supports more accurate reporting and efficient case review.

A strategic collaboration with Proscia

For Fanny Sockeel, CEO of Primaa, this collaboration represents a major milestone:
“We are proud to bring Cleo Skin’s capabilities to Concentriq. Together, we are enabling dermatopathologists to deliver faster and more confident results, while giving laboratories even more reasons to advance their AI journey with confidence.”

By joining the Proscia Ready partner alliance, Primaa becomes part of a network of global solution providers accelerating the adoption of digital pathology. This collaboration reinforces one of the industry’s most comprehensive portfolios of AI applications, combining Primaa’s expertise in AI algorithms with Proscia’s leading digital pathology platform.

Towards a new era of augmented pathology

This partnership highlights a shared vision: combining human expertise and artificial intelligence to deliver faster, more consistent, and reliable diagnostic insights in digital dermatopathology. By integrating Cleo Skin into Concentriq, Primaa and Proscia are enabling laboratories to harness AI effectively while supporting pathologists in making confident decisions in one of the most challenging areas of pathology.

About Proscia

Proscia is rewiring pathology for precision medicine to improve patient outcomes. Its software, AI, and real-world data fuel the development and use of novel therapies and diagnostics, driving the fight against humanity’s most challenging diseases, like cancer. 16 of the top 20 pharmaceutical companies and a global laboratory network on track to deliver more than 8 million diagnoses annually rely on Proscia’s solutions each day. For more information, visit proscia.com.

About Primaa
Primaa develops artificial intelligence software capable of detecting various cancer biomarkers. The Cleo Breast (for breast) and Cleo Skin (for skin) tools support physicians in making their diagnoses, providing greater reliability and optimizing the time required for examination analysis. Co-founded in 2018 by Marie Sockeel, pathologist, together with Fanny Sockeel and Stéphane Sockeel, the company counts 25 employees.